CRH Medical (TSE:CRH) was upgraded by analysts at Bloom Burton from an “accumulate” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports.
Shares of CRH Medical stock traded down C$0.12 during trading on Thursday, reaching C$3.87. The company’s stock had a trading volume of 191,000 shares, compared to its average volume of 106,492. The company has a quick ratio of 2.15, a current ratio of 2.23 and a debt-to-equity ratio of 51.90. CRH Medical has a 12-month low of C$3.37 and a 12-month high of C$5.91. The firm has a market capitalization of $276.39 million and a P/E ratio of 82.34. The business’s 50 day simple moving average is C$3.74.
CRH Medical (TSE:CRH) last posted its quarterly earnings results on Wednesday, July 31st. The company reported C$0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of C$0.01 by C$0.02. The business had revenue of C$40.78 million during the quarter, compared to analysts’ expectations of C$39.53 million. Analysts predict that CRH Medical will post 0.12 EPS for the current fiscal year.
CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.
See Also: Dividend Yield
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.